Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

Summary

The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients

Timeline

Start

2017-05-04

Primary completion

2017-12-29

Completion

2017-12-29

Outcome

Met primary endpoint

registry analysis (other test); NVA237 50 ug vs Placebo; p <0.001; Linear Mixed Model (LMM) 0.089 (95% CI 0.047 to 0.132); Linear Mixed Model NCT03137784 ↗

registry analysis (other test); NVA237 25 ug vs Placebo; p <0.001; Linear Mixed Model (LMM) 0.090 (95% CI 0.047 to 0.132); Linear Mixed Model NCT03137784 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glycopyrrolate	Small molecule	25 ug	—
Subject	Glycopyrrolate	Small molecule	50 ug	—

Indications